Headlines

Go To Pro Hockey Rumors
Go To Hoops Rumors

Chris Sale

NL East Notes: Sale, Montas, Wood

By | at

Braves left-hander Chris Sale just had a tremendous bounceback season. He made 29 starts with a 2.38 earned run average, earning a National League Cy Young award. He was largely injured and/or ineffective from 2019 to 2023, which had him pondering retirement.

“I thought that it was gonna be my last year,” Sale said to the Baseball Isn’t Boring podcast about where he was at before getting traded to Atlanta. “So I went into that offseason on a mission like ’one more year left.’… ’cause in my mind, I wasn’t walking away from baseball. I was walking away from getting hurt.”

The Red Sox traded Sale to Atlanta for Vaughn Grissom in December of 2023. At the time, as mentioned, he had been battling significant injuries for five years. Tommy John surgery in 2020 was the big one but Sale also had a stress reaction in his ribs, a fractured finger, a broken wrist suffered in a bicycle accident and a stress reaction in his shoulder blade over that span. He had a 4.16 ERA in 298 1/3 innings over those five seasons.

2024 was the final year of his extension with the Red Sox and the mounting injuries apparently had him looking towards hanging up his spikes. But he was traded to Atlanta, signed an extension that covered 2024 and 2025 with a club option for 2026, and then went on to have an excellent season in 2024. It makes for an interesting “what if” but Sale is clearly in a better spot now. The injury bug hasn’t left him entirely alone, however. He missed the final two weeks of 2024 due to back spasms and was also left off Atlanta’s postseason roster. 2024 was still a big improvement over prior years but time will tell if he can keep the good health going into his age-36 season.

Some more spring training tidbits from the NL East…

  • It was reported earlier this week that Mets righty Frankie Montas has a lat strain and will be shut down for six to eight weeks. The righty is apparently a bit more optimistic than his club, however. He told members of the media today, including Anthony DiComo of MLB.com, that he’s already feeling better from his platelet-rich plasma injection and expects to be throwing again in four to six weeks. That’s still a notable period of time but it’s a bit less dire than the other timeline. He had a 4.84 ERA last year and then signed a two-year, $34MM deal with the Mets this winter. He will have the chance to opt out after the first year, though returning healthy and productive will be important if he is to consider that possibility. For now, the Mets’ rotation mix includes Sean Manaea, Kodai Senga, David Peterson, Clay Holmes, Paul Blackburn, Griffin Canning and Tylor Megill.
  • Nationals outfielder James Wood has some quad tendinitis, per Andrew Golden of The Washington Post. It doesn’t bother him when he hits, so he’s been able to take batting practice but has skipped some defensive drills. Per Mark Zuckerman of MASNsports.com, Wood says he has “zero” concern but the club did send him for an MRI, which showed no structural damage. With still over a month before Opening Day, there’s plenty of time to get things in order, with Wood and the Nats both surely hoping for a clean bill of health by then. Now just 22 years old, Wood hit .264/.354/.427 in his major league debut last year and is slated to be a big part of the club’s future.

Chris Sale Wins National League Cy Young Award

By | at

Braves left-hander Chris Sale has been named the National League Cy Young Award winner for 2024, per an announcement from the Baseball Writers Association of America. Zack Wheeler of the Phillies finished in second place with Paul Skenes of the Pirates in third place.

The award is the final cherry on top of a remarkable comeback season for Sale. He had a run from 2010 to 2018 of being one of the best pitchers in the majors, but struggled in 2019 and then was in the injury wilderness for quite a while. Due to various ailments, including Tommy John surgery, he only pitched about 150 innings total from 2020 to 2023.

The Red Sox flipped him to Atlanta almost a year ago, in December of 2023. The move was seen as risky at the time, as Sale was going into his age-35 season and was several years removed from his prime.

On top of that, Atlanta sent Vaughn Grissom to Boston in the deal, a notable prospect who still had years and years of cheap control. In return, they were getting just one year of Sale, though they did sign him to an extension that covered 2024 and 2025 with a club option for 2026. That extended their window of control over him, but at a fairly hefty price point: $38MM for the two guaranteed years plus $18MM for the option.

But so far, the deal has been incredibly lopsided in favor of Atlanta. Grissom was injured for much of 2024 and didn’t perform well while healthy. For Atlanta, most of their key contributors got hurt this year while Sale ironically stayed healthy, in spite of his recent track record.

Sale finished the season having made 29 starts and thrown 177 2/3 innings, allowing 2.38 earned runs per nine. He struck out 32.1% of batters faced, only gave out walks 5.6% of the time and got grounders on 44.8% of balls in play. He won the pitching triple crown by leading the National League in ERA, wins and strikeouts. His tally of 6.4 wins above replacement from FanGraphs was easily the most in the majors this year, with Tarik Skubal of the Tigers second at 5.9 fWAR.

Despite his previous dominance, this is actually Sale’s first time taking home the hardware. Per MLB’s Sarah Langs on X, Sale is the first pitcher to finish top five in Cy Young voting in five straight years, fall outside the top five for five straight years immediately after, followed by a return to the top five. He is also (X links from Langs) the first pitcher to have six previous top five finishes and later win the award, in addition to being one of the five oldest pitchers to win for the first time.

Sale got 26 of the first place votes (full vote tallies from the BBWAA), with the other four going to Wheeler, who logged exactly 200 innings over 32 starts with a 2.57 ERA. Skenes already won Rookie of the Year award earlier this week but this further cements what an amazing season he had. Other pitchers getting votes were Dylan Cease, Shota Imanaga, Logan Webb, Michael King, Hunter Greene, Ryan Helsley, Cristopher Sánchez, Reynaldo López, Sean Manaea and Aaron Nola.

Gold Glove Winners Announced

By | at

Major League Baseball announced the Gold Glove winners tonight, as selected by a group of managers, coaches, and statistical analysis.  Twenty-five percent of the selection total was determined by SABR’s Defensive Index metrics, while the other 75 percent was determined by votes from all 30 managers and up to six coaches from each team.  The utility Gold Glove was determined in a separate fashion, via a defensive formula calculated by SABR and Rawlings.

National League winners….

American League winners….

Chris Sale Not On Braves’ Wild Card Roster

By | at

The Braves announced their roster for the Wild Card series today and it does not include left-hander Chris Sale. The club is going with an even split of 13 pitchers and position players, the latter group including two catchers, five infielders and six outfielders.

Sale had an excellent bounceback season in 2024 and could be awarded a Cy Young trophy in a few weeks, but the campaign ended on a frustrating note. He hasn’t taken the mound since September 19 against the Reds. In that outing, Sale’s velocity was down and he hasn’t pitched since. Up until yesterday, it seemed as though the club was just holding Sale to see if they would need him for a do-or-die game, otherwise hoping to hold him back for the first game of the Wild Card round.

Going into yesterday’s double-header, which was necessitated after two midweek games between the Mets and Atlanta were delayed by Hurricane Helene, both clubs needed a victory to secure a playoff spot. Spencer Schwellenbach started Game 1, which the Mets went on to win 8-7. It was expected that Sale would take the ball for the second contest but the club then announced that Sale had been scratched with back spasms. The issue had flared up during that start against the Reds and he kept hoping to be able to return to the mound but it didn’t improve and then worsened on Sunday night, per Mark Bowman of MLB.com (X links).

Based on Sale being left off the Wild Card roster, it can be assumed that the club doesn’t expect him to be game ready in the next few days. As mentioned, he is having a great season and undoubtedly would have been a part of their plans if he were healthy. He made 29 starts this year with a 2.38 earned run average, 32.1% strikeout rate, 5.6% walk rate and 44.8% ground ball rate.

Without Sale, the club will have to get creative to survive against the Padres. Due to the aforementioned double-header situation, they used a lot of arms yesterday. Schwellenbach started the first game and Grant Holmes the second. Neither of those pitchers are on the roster either, which makes sense since they probably wouldn’t be available for a few days anyway.

Max Fried and Reynaldo López will likely start game two and three respectively, as they would be on normal rest for those contests following their last regular season outings. Charlie Morton started on Sunday and might not be available early in the series, though he is on the roster.

For today, the club may be looking to get some innings out of Bryce Elder or AJ Smith-Shawver. Neither has been a huge part of the club’s performance of late but they may need to step up while the bullpen is taxed and the club can’t turn to Sale, Schwellenbach or Holmes. Elder posted a 6.52 ERA in the big leagues this year while frequently being optioned to the minors. He had a solid 3.73 ERA in Triple-A this year but hasn’t pitched for the big league club since August 6.

Smith-Shawver only pitched once in the majors this year, a spot start of 4 1/3 innings in May. He has a 4.85 ERA in Triple-A on the year, though he finished somewhat strong with a 3.68 ERA over his last seven starts.

In addition to Elder and Smith-Shawver, Atlanta’s playoff roster consists of Fried, Lopez, Morton, Aaron Bummer, Jesse Chavez, Daysbel Hernández, Raisel Iglesias, Luke Jackson, Joe Jiménez, Pierce Johnson and Dylan Lee. On the position player side, they have catchers Sean Murphy and Travis d’Arnaud, infielders Ozzie Albies, Orlando Arcia, Whit Merrifield, Matt Olson and Gio Urshela, as well as outfielders Michael Harris II, Jarred Kelenic, Ramón Laureano, Marcell Ozuna, Jorge Soler and Eli White.

The Other, Other NL MVP Candidate

By | at

For much of the season Shohei Ohtani has been the presumptive National League MVP favorite. Maybe that wasn't the case on Opening Day, but an injury to teammate Mookie Betts early in the summer and an injury to D-backs star infielder Ketel Marte cleared his path. The Ohtani hype is understandable. He's been the National League's best hitter this year by many measures, pacing the Senior Circuit in slugging percentage (.613) and wRC+ (167). Ohtani is fifth in the NL in batting average, fourth in OBP, first in homers and runs scored and second in runs batted in. He's also swiped 46 bags and is a veritable lock to have a 45-45 season, with a chance at becoming MLB's first ever 50-homer, 50-steal player in a season.

Lately, there's been a push by Mets shortstop Francisco Lindor to tighten the race, however. Dating back to July 1, Lindor boasts a sensational .310/.384/.587 slash. He's in the midst of a torrid 15-game hitting streak, which he started just one game after seeing a 12-game hitting streak end. Since the beginning of July, Lindor has more than twice as many multi-hit games (22) than he does hitless games (10). Defensive metrics are a bit split on him this year, with Defensive Runs Saved curiously pegging him as average while Statcast grades him as one of the best defensive players in the entire game. Regardless, Lindor and his .274/.343/.501 batting line (plus 30 homers and 26 steals)  lead the NL in both FanGraphs and Baseball-Reference WAR.

It's not quite fair to the rest of the field to call this a pure two-horse race, though Lindor and Ohtani are certainly the favorites at the moment. Cincinnati standout Elly De La Cruz could thrust himself further into the conversation with a big finish, but many voters will be turned off by the fact that however excellent his season has been -- and it's been excellent -- it's happened as a member of a non-contending Reds club.

There's still one other viable MVP candidate who's not getting the love, and who probably won't get the love -- but absolutely should.

Unlock Subscriber-Exclusive Articles Like This One With a Trade Rumors Front Office Subscription

BENEFITS
  • Access weekly subscriber-only articles by Tim Dierkes, Steve Adams, and Anthony Franco.
  • Join exclusive weekly live chats with Anthony.
  • Remove ads and support our writers.
  • Access GM-caliber tools like our MLB Contract Tracker

AL East Notes: Sale, Tiedemann, Ramirez

By | at

The Chris Sale-for-Vaughn Grissom trade between the Braves and Red Sox caught many in baseball by surprise, including Sale himself.  The veteran southpaw related in a recent appearance on the “Baseball Isn’t Boring” podcast (hat tip to WEEI.com’s Rob Bradford) that being dealt “wasn’t even in the realm of possibilities.  That wasn’t even a thought that crossed my mind” heading into the offseason.  As Sale plainly put it, “Why would anybody want me at this point?” in the wake of multiple injury-plagued seasons.

There was also the factor of Sale’s 10-and-5 no-trade rights, so he could’ve rejected the chance to join the Braves.  However, after less than a day of discussing things with his family and inner circle, Sale okayed the deal, with some Grapefruit League geography playing a major role.  The Braves’ spring facility in North Port, Florida adds only roughly an hour to Sale’s commute from his home, so “I can still live my life while being part of this team in spring training.  That was probably the most important thing.  One hundred percent.  My kids play sports.  They’ve got school stuff going on.”  Sale also relayed the amusing item that the first proper conversation he had with Red Sox chief baseball officer Craig Breslow after weeks of texts and “phone tag” was when Breslow let Sale know the trade was in the works.

More from around the AL East…

  • Top Blue Jays pitching prospect Ricky Tiedemann is day-to-day with inflammation in his calf and hamstring area, manager John Schneider told Sportsnet’s Shi Davidi (X links) and other reporters.  It doesn’t seem like Tiedemann will be sidelined for too long since an MRI didn’t reveal any structural damage, though any kind of injury setback is perhaps more concerning given how Tiedemann missed big chunks of the 2023 season due to shoulder and biceps injuries.  After pitching just 44 minor league innings last year, Tiedemann is going to be built up slowly and steadily to the point where the Jays hope he can take on more of a regular starter’s workload, and perhaps make his MLB debut before 2024 is through.
  • Despite multiple trade rumors over the last few months, Harold Ramirez is still with the Rays, and he tells John Romano of the Tampa Bay Times that he is just focused on baseball as Spring Training games get underway.  Ramirez will earn $3.8MM this season and is arbitration-eligible next winter as well, leading to speculation that the Rays might be open to dealing an increasingly-expensive (by their payroll standards) player with limited defensive value as an outfielder.  Romano also notes that the recent signing of Amed Rosario brought another right-handed outfield option into the mix, so it still wouldn’t be a surprise if Tampa swung a late deal to move Ramirez prior to Opening Day.

NL East Notes: Harper, Sale, Crick

By | at

After his recovery from Tommy John surgery necessitated a move to first base last season, Bryce Harper took well enough to his new position that the Phillies announced in November that Harper would be their regular first baseman in 2024 and beyond.  The two-time NL MVP spoke to reporters (including The Athletic’s Matt Gelb) about the situation today, saying “I wanted them to know that I was on board with anything they wanted to do,” and that Harper left the decision about his position up to the club.  “I said if you want me in right field, I’ll play right.  If you want me at first, I’ll play first base.  I think collectively, they said, first base is where we want you.  I said, ’OK, I’ll do everything I can to be there,’ ” Harper said.  He is now spending his Spring Training further working on what seems to be his permanent new position, noting that “I don’t think I’ll move back out to right.  I don’t.  But never say never.”

Harper also confirmed that he is interested in extending his contract, as agent Scott Boras stated in December.  The idea caught many by surprise given that Harper still has eight seasons and $196MM remaining on his original 13-year, $330MM contract, and he’ll be turning 39 years old in October 2031.  While Harper said “I haven’t really thought too much about” his contract situation, he said that “playing into my 40’s, I mean, that’s the biggest thing for me.  So I want to get that done.”  It remains to be seen if Harper, Boras, and the Phillies could possibly reach some kind of deal to add two (or more?) years onto Harper’s contract, yet president of baseball operations Dave Dombrowski has downplayed the idea of a renegotiation.

More from around the NL East…

  • Chris Sale has battled through several injury-plagued seasons, but the winter of 2023-24 “was the first time going into an offseason without dealing with something since 2018 or something like that,” the new Braves starter told The Athletic’s David O’Brien and other reporters.  “It’s been a long time.  I had a lot of fun this offseason, being able to play baseball and do things that I haven’t been able to do.”  In both acquiring Sale from the Red Sox and then signing him to a two-year extension, the Braves are putting a lot of faith that the southpaw is ready to rebound as he enters his age-35 season.  Atlanta even looked into acquiring Sale during the 2023 season, according to manager Brian Snitker.
  • Mets reliever Kyle Crick is recovering from a Grade 4 calf strain and might not start throwing bullpens until closer to the end of spring camp, MLB.com’s Anthony DiComo writes.  New York signed Crick to a minor league deal in December and he has no issue with pitching in the minors for the start of the season, given how his injury will seemingly prevent him making the Opening Day roster.  Crick posted a 3.56 ERA over 187 1/3 relief innings with the Giants, Pirates, and White Sox from 2017-22, though he didn’t pitch in 2023 until surfacing in Dominican Winter League action a few months ago.
  • There’s enough happening within the division that this is our second batch of NL East Notes today.  Earlier on, Nick Deeds compiled another set of items about the Marlins, Phillies, Nationals, and Braves.

Braves, Chris Sale Agree To Two-Year Deal

By | at

The Braves and left-hander Chris Sale have agreed to a new deal, which will pay him $38MM over the next two years. The Wasserman client will earn $16MM in 2024 and $22MM in 2025 and there’s also an $18MM club option for 2026. Sale was already under contract via an extension he previously signed with the Red Sox but this will overwrite that.

Sale was acquired from the Red Sox last week, in a trade that sent Vaughn Grissom to Boston. The Sox also included $17MM to cover the remainder of Sale’s contract, a five-year, $145MM extension he and the Red Sox signed in 2019. As part of that deal, Sale was set to make $27.5MM in 2024, though $10MM of that was deferred until 15 years in the future. With the $17MM coming from the Sox, Atlanta was only going to be paying him $500K. There was also a $20MM club option for 2025.

As part of this new deal, Sale’s $16MM salary will be pretty close to the non-deferred money he was going to make in 2024. He will no longer have that deferred $10MM payment down the road, but he will have $22MM locked in for the 2025 season. That gives him some extra security in the event of more health problems cropping up this year. Sale pitched less than 50 total innings over the 2020-2022 period, mostly due to Tommy John surgery but also due to other ailments. Last year, he was able to toss 102 2/3 frames but a stress reaction in his shoulder blade kept him out of action for over two months. Any further health issues would have perhaps given the club some hesitation about picking up the 2025 option but Sale has now locked in a notable salary for next year.

For Atlanta, this is a show of faith in the soon-to-be-35-year-old. They could have simply employed Sale for 2024 and then walked away if things didn’t go well, with the club option there to keep him around if he had a strong campaign for his new club. But they have now committed themselves to at least two years of Sale, with the club option now kicked down the road to 2026. As mentioned, Sale hasn’t been fully healthy in the past four years and even had some issues before that. Some shoulder and elbow issues kept him around 150 innings in 2018 and 2019, meaning his last fully healthy campaign was 2017.

Back then, Sale was one of the best pitchers in the league, finishing that 2017 season with a 2.90 ERA. Last year, he wasn’t quite as dominant, with a 4.30 at the end of the season. The peripherals were a bit better, however, with a 29.4% strikeout rate and 6.8% walk rate that were both strong.

Despite that fairly solid bounceback season, it’s obviously a gamble to bet on a pitcher that has been hurt so much, locking him up for his age-35 and age-36 seasons. But the club has a decent amount of rotation uncertainty going forward. Max Fried is entering his final year of club control while Charlie Morton is one year from free agency as well. Morton has flirted with retirement before and is going into his age-40 season, making it possible he won’t be back in 2025.

Prior to this deal, Sale was a potential to depart as well, depending on the outcome of the club option. Now that he’s under contract for 2025, he can be pencilled into next year’s rotation next to Spencer Strider. The club will still have to fill out the rest of the rotation, but perhaps internal options like Bryce Elder, AJ Smith-Shawver and Hurston Waldrep will have taken steps forwards between now and then.

There’s also the competitive balance tax to consider. Under the current collective bargaining agreement, a player’s CBT hit is recalculated when he is traded to reflect what remains of the contract. That means that Sale was going to have a $27.5MM CBT hit prior to this deal, with the Sox absorbing $17MM of that. But that will now drop to $19MM, leaving just $2MM on Atlanta’s CBT ledger this year but $19MM next year. Going into today, the club’s CBT figure was at $276MM, per Roster Resource. That’s right against the third tax threshold of $277MM, which is a notable line to cross. Clubs that go over the third threshold have their top pick in the next draft pushed back by 10 slots, in addition to an increased tax rate. By lowering Sale’s CBT hit, the club will have a bit more breathing room to make more moves, either now or during the season.

Ultimately, it’s a pact that works for both sides. Atlanta gets a bit more luxury tax space and also, hopefully, a better rotation outlook in 2025 and maybe even 2026. Sale, meanwhile, locks in some future earnings to guard against any continued health issues.

MLBTR Podcast: Yamamoto Fallout, the Sale/Grissom Trade and Transaction Roundup

By | at

The latest episode of the MLB Trade Rumors Podcast is now live on Spotify, Apple Podcasts, and wherever you get your podcasts! Make sure you subscribe as well! You can also use the player at this link to listen, if you don’t use Spotify or Apple for podcasts.

This week, host Darragh McDonald is joined by Anthony Franco of MLB Trade Rumors to discuss…

Check out our past episodes!

The podcast intro and outro song “So Long” is provided courtesy of the band Showoff.  Check out their Facebook page here!

Braves, Red Sox Trade Chris Sale For Vaughn Grissom

By | at

The Braves and Red Sox have agreed to a major trade, as left-hander Chris Sale will head to Atlanta in exchange for infield prospect Vaughn Grissom, ESPN’s Jeff Passan reports.  The Sox will also include $17MM in the deal to help cover Sale’s $27.5MM salary for the 2024 season, as per the Boston Globe’s Alex Speier.  Sale had a full no-trade clause that he has waived to facilitate the move.

The surprising move ends Sale’s tumultuous run in Boston after seven years and six seasons, as Sale missed all of the 2020 campaign.  After acquiring Sale as part of a blockbuster deal with the White Sox in December 2016, Sale pitched brilliantly in his first two seasons at Fenway, twice finishing in the top four in AL Cy Young Award voting and playing a big role in Boston’s World Series title in 2018.

Since 2019 was the last year of Sale’s previous contract, the Red Sox were aggressive in locking up their ace, signing him to a five-year, $145MM extension covering the 2020-24 seasons, with a $20MM club option for the 2025 campaign.  Unfortunately, this extension has proven to be a big misfire, as Sale started to run into injury problems even late in the 2018 campaign.  He was shut down in August 2019 with elbow inflammation and received a PRP injection, yet that elbow issue was only the harbinger for the Tommy John surgery that cost Sale his entire 2020 season and most of his 2021 campaign.

The bad injury luck continued over the last two seasons, as Sale was sidelined by a wide array of maladies including a stress reaction in his ribs, a fractured finger, a broken wrist (suffered in a bicycle accident), and a stress reaction in his shoulder blade.  Sale tossed only 48 1/3 innings total in 2021-22, while rebounding to some extent to pitch 102 2/3 frames last season.

Sale’s 93.9mph fastball velocity in 2023 slightly topped his career average, while his strikeout, walk, and hard-hit ball rates were all well above the league average.  While the southpaw may never get back to his past elite form, Sale’s 2023 performance at least indicated that he still has a good deal left in the tank as he enters his age-35 season, provided that he can just stay on the field.

This is exactly what the Braves are counting on from Sale as a third or even a fourth starter, behind Max Fried, Spencer Strider, and Charlie Morton in the team’s rotation.  President of baseball operations Alex Anthopoulos is counting in Sale’s upside to bolster the pitching staff, and Atlanta’s collection of younger arms (AJ Smith-Shawver, Dylan Dodd, Huascar Ynoa, Darius Vines, and top prospect Hurston Waldrep) and swingman Reynaldo Lopez can provide extra depth should Sale or anyone else in the rotation need time on the injured list.

In typical Anthopoulos fashion, this particular trade came out of nowhere, even if the Braves were known to be looking for some pitching help.  Atlanta made a strong bid for Aaron Nola before he re-signed with the Phillies, and such free agent and trade targets as Tyler Glasnow, Dylan Cease, Sonny Gray, and Seth Lugo were also linked to the Braves on the rumor mill.

Because Sale’s extension the Red Sox contained $10MM of deferred money per season, he’ll cost the Braves merely $500K in actual salary in 2024.  Even without the deferral involved, a one-year, $10.5MM deal for Sale as a free agent would’ve been a reasonable or even a slight bargain price for a pitcher with his track record.  It could perhaps be argued that the Braves might have been better off finding such a pitcher on the free agent market rather than trade away a promising young player like Grissom, but it is also fair to note that such a rotation upgrade might not have existed at a $10.5MM price tag.  Or, dealing for a pitcher like Cease, Corbin Burnes, Shane Bieber, or other still-available trade candidates might’ve cost Atlanta lot more than only Grissom.

Sale’s $20MM club option for 2025 shouldn’t be discounted either, as the Braves might consider exercising that option if Sale pitched well.  The $20MM figure matches what Morton is earning this season, and since Morton has flirted with retirement over the last few years, Sale could potentially step in as Atlanta’s veteran rotation arm if Morton does hang up his cleats next winter.  Sale’s $20MM club option is actually a vesting option that becomes guaranteed if he finishes the year healthy, and finished in the top 10 in NL Cy Young Award voting.

Anthopoulos and team chairman Terry McGuirk weren’t kidding last November when they said that the Braves planned to keep increasing payroll.  The Braves’ $203MM Opening Day payroll from 2023 was already a club record, and Roster Resource now projects a payroll just shy of $241MM for the 2024 squad.  After topping the luxury tax barrier for the first time in 2023, the Braves’ estimated $280MM tax number now soars over the third penalty tier of $277MM, so they’ll face increasingly hefty overages as second-time payors.  Passing the third tier means that Atlanta’s top pick in the 2024 draft will now drop 10 spots, and they’ll face the standard tax penalties related to qualified free agents and the international bonus pool.

This doesn’t appear to be much of a deterrent for an Atlanta club that has been swimming in extra revenues since the opening of Truist Park and its neighboring ballpark village project known as The Battery.  The Braves have used this money to lock up several members of its roster on contract extensions, and this young core has already delivered the 2021 World Series championships and six straight NL East crowns.

The outlook hasn’t been as rosy at Fenway Park, as the Red Sox have been very inconsistent since that 2018 title.  On the heels of consecutive last-place finishes in the AL East, Craig Breslow replaced Chaim Bloom as the team’s chief baseball officer, and Breslow now has his first true blockbuster trade as a front office executive.

Starting pitching has been a known need for the Red Sox all winter, and Boston just signed Lucas Giolito yesterday to help address the rotation mix.  While moving Sale diminishes from the number of available arms, the trade does free up some money to help make other moves, and the Sox simply might’ve wanted a more reliable starting pitching option than the injury-plagued Sale.  Plus, adding six years of team control over a promising player like Grissom is a nice return for the Sox at the cost of $17MM.

Grissom immediately fills Boston’s need for second base help.  An 11th-round pick for Atlanta in the 2019 draft, Grissom has torn up minor league pitching during his four seasons in the Braves’ farm system and quickly got himself on the radar for a big league call-up.  Grissom hit .291/.353/.440 over 156 plate appearances in 2022, though followed up with a more modest .659 OPS in just 80 PA last season.  Given a chance at the everyday shortstop job, Grissom fell behind Orlando Arcia on the depth chart, and ultimately spent most the season at Triple-A since the Braves wanted him to play regularly rather than ride the bench.

Grissom has spent much of his minor league career as a shortstop, yet there has been some question about his long-term viability at the position.  Moving to second base or third base was difficult on a Braves team with Ozzie Albies and Austin Riley already in place, so Grissom had been getting some reps as an outfielder as a possible candidate to fill the club’s left field vacancy.  However, the acquisition of Jarred Kelenic from the Mariners also seemed to close that door.

No such position blocks exist in Boston, as the Red Sox might well just install Grissom as their Opening Day second baseman.  He fits Breslow’s preferred add of a right-handed hitter, and Grissom’s glovework could or should work out well at the less-demanding second base position.  Getting Grissom in the fold could now relegate Enmanuel Valdez, Pablo Reyes, or Rob Refsnyder to pure backup duty or perhaps even as trade chips, while Ceddanne Rafaela now looks even likelier to be used as an outfielder (and Rafaela might yet be a trade candidate himself).

Photo courtesy of USA Today Sports Images

Show all

MLB Trade Rumors is not affiliated with Major League Baseball, MLB or MLB.com

hide arrows scroll to top